Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program
European Journal of Cancer2020Vol. 142, pp. 102–111
Citations Over TimeTop 10% of 2020 papers
Laurence Albigès, Aude Fléchon, Christine Chevreau, Delphine Topart, Gwénaëlle Gravis, Stéphane Oudard, Jean Marc Tourani, Lionnel Geoffrois, Émeline Meriaux, Antoine Thiery-Vuillemin, Philippe Barthélémy, Sylvain Ladoire, Brigitte Laguerre, Valérie Perrot, Anaïs Billard, Bernard Escudier, Marine Gross‐Goupil
Related Papers
- → Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma(2019)3 cited
- → Supplementary Table from Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma(2023)
- → Supplementary Table from Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma(2023)
- → Supplementary Data from Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma(2023)
- → Supplementary Figure from Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma(2023)